KR960037063A - 인터페론 용액 - Google Patents

인터페론 용액 Download PDF

Info

Publication number
KR960037063A
KR960037063A KR1019960010123A KR19960010123A KR960037063A KR 960037063 A KR960037063 A KR 960037063A KR 1019960010123 A KR1019960010123 A KR 1019960010123A KR 19960010123 A KR19960010123 A KR 19960010123A KR 960037063 A KR960037063 A KR 960037063A
Authority
KR
South Korea
Prior art keywords
interferon
amount
buffer
benzyl alcohol
interferon solution
Prior art date
Application number
KR1019960010123A
Other languages
English (en)
Other versions
KR100212346B1 (ko
Inventor
그로스 귄터
델 테르조 사비노
칸다쿠리 쿠마르 사란
Original Assignee
프리돌린 클라우스너 , 롤란드 보러
에프. 호프만-라 롯슈 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프리돌린 클라우스너 , 롤란드 보러, 에프. 호프만-라 롯슈 아크티엔게젤샤프트 filed Critical 프리돌린 클라우스너 , 롤란드 보러
Publication of KR960037063A publication Critical patent/KR960037063A/ko
Application granted granted Critical
Publication of KR100212346B1 publication Critical patent/KR100212346B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)

Abstract

본 발명은 (a) 인터페론 알파; (b) 비이온성 세제; (c) pH 4.5∼5.5로 조절하기 위한 완충제; (d) 벤질알콜; 및 선택적으로 (e) 등장화제를 포함하는 인터페론 수용액에 관한 것이다.

Description

인터페론 용액
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (2)

  1. (a) 인터페론-알파; (b) 비이온성 세제; (c) pH 4.5∼5.5로 조절하기 위한 완충제; (d) 벤질알콜; 및 선택적으로 (e) 등장화제를 포함하는 인터페론 수용액.
  2. 제1항에 있어서, 인터페놀-알파의 양이 106내지 108IU/㎖이고; 비이온성 세제의 양이 약 0.01 내지 0.5㎎/㎖이고; 완충제의 농도가 약 10 내지 15밀리몰이고; 벤질 알콜의 양이 약 8 내지 20㎎/㎖인 인터페론 수용액.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960010123A 1995-04-06 1996-04-04 인터페론 용액 KR100212346B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95105166.3 1995-04-06
EP95105166 1995-04-06

Publications (2)

Publication Number Publication Date
KR960037063A true KR960037063A (ko) 1996-11-19
KR100212346B1 KR100212346B1 (ko) 1999-08-02

Family

ID=8219166

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960010123A KR100212346B1 (ko) 1995-04-06 1996-04-04 인터페론 용액

Country Status (32)

Country Link
US (1) US5762923A (ko)
EP (1) EP0736303B1 (ko)
JP (1) JP2758154B2 (ko)
KR (1) KR100212346B1 (ko)
CN (1) CN1066065C (ko)
AR (1) AR002932A1 (ko)
AT (1) ATE183650T1 (ko)
AU (1) AU685356B2 (ko)
BR (1) BR9601276A (ko)
CA (1) CA2172664C (ko)
CO (1) CO4750807A1 (ko)
CY (1) CY2194B1 (ko)
CZ (1) CZ287626B6 (ko)
DE (1) DE69603894T2 (ko)
DK (1) DK0736303T3 (ko)
ES (1) ES2136910T3 (ko)
GR (1) GR3031775T3 (ko)
HK (1) HK1012232A1 (ko)
HU (1) HU227643B1 (ko)
IL (1) IL117752A (ko)
MA (1) MA23838A1 (ko)
MY (1) MY113594A (ko)
NO (1) NO316801B1 (ko)
NZ (1) NZ286300A (ko)
PE (1) PE38897A1 (ko)
PL (1) PL183873B1 (ko)
RU (1) RU2113845C1 (ko)
SA (1) SA96160728B1 (ko)
SG (1) SG52806A1 (ko)
TR (1) TR199600287A2 (ko)
TW (1) TW426523B (ko)
ZA (1) ZA962553B (ko)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
SK284989B6 (sk) * 1996-12-24 2006-04-06 Biogen, Inc. Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
KR100420642B1 (ko) * 1998-03-26 2004-03-02 쉐링 코포레이션 Ｐｅｇ-인터페론 알파 결합체의 보호에 사용되는 제형
JP2002510653A (ja) * 1998-04-03 2002-04-09 カイロン コーポレイション 緩衝剤としてコハク酸を含有する注射可能なｉｇｆ処方物
SK288038B6 (en) 1998-05-15 2013-01-02 Merck Sharp & Dohme Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection
ES2251196T3 (es) * 1998-06-08 2006-04-16 F. Hoffmann-La Roche Ag Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica.
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
JP4719357B2 (ja) * 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CN1896231B (zh) * 1998-08-06 2012-09-05 山景药品公司 分离四聚体尿酸氧化酶的方法
JP2002532556A (ja) * 1998-12-22 2002-10-02 シェリング・コーポレーション Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
HU230057B1 (hu) 1999-04-08 2015-06-29 Merck Sharp & Dohme Corp. Melanóma-kezelés
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
EP1276756A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
DE60139339D1 (de) 2000-11-07 2009-09-03 Novartis Vaccines & Diagnostic Stabilisierte interferonzusammensetzungen
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
EP1506786B1 (en) 2002-05-21 2016-11-23 Daiichi Sankyo Company, Limited Medicinal compositions containing ghrelin
PL1610822T5 (pl) 2003-04-02 2019-05-31 Ares Trading Sa Płynne formulacje farmaceutyczne FSH i LH z niejonowym surfaktantem
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
DK1638595T3 (da) 2003-06-20 2013-04-08 Ares Trading Sa Frysetørrede FSH-/LH-formuleringer
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
KR20070012464A (ko) 2004-05-17 2007-01-25 아레스 트레이딩 에스.아. 하이드로겔 인터페론 제제
CN1993139B (zh) * 2004-06-01 2011-02-16 阿雷斯贸易股份有限公司 稳定的干扰素液体制剂
CN1993138B (zh) * 2004-06-01 2010-12-15 阿雷斯贸易股份有限公司 稳定蛋白质的方法
CN101039660B (zh) 2004-08-12 2010-10-06 先灵公司 稳定的聚乙二醇化干扰素制剂
CN101022822B (zh) * 2004-08-24 2012-06-27 第一三共株式会社 生理学活性肽的液体制剂
LT3321359T (lt) 2005-04-11 2021-05-10 Horizon Pharma Rheumatology Llc Urato oksidazės variantinės formos ir jų panaudojimas
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2008026044A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Pharmaceutical compositions of bupropion
CA2675233A1 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
CA2698396C (en) * 2007-09-04 2014-01-21 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof
CA2698173C (en) * 2007-09-04 2015-02-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof
EP2212432A4 (en) * 2007-10-22 2011-10-19 Schering Corp COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
EA201070773A1 (ru) 2007-12-20 2010-12-30 Мерк Сероно С. А. Составы пэг-интерферона-бета
AU2009256547B2 (en) 2008-06-13 2014-07-10 Proyecto De Biomedicina Cima, S.L. Apo-A conjugates for the administration of biologically active compounds
JP2012502906A (ja) * 2008-09-17 2012-02-02 ネクター セラピューティックス オリゴマー−プロテアーゼ阻害剤コンジュゲート
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102526758B (zh) * 2012-02-23 2013-02-13 北京三元基因工程有限公司 一种聚乙二醇化干扰素稳定的水溶液
TWI726291B (zh) 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
CN107073080A (zh) * 2014-09-23 2017-08-18 豪夫迈·罗氏有限公司 包含α‑型干扰素的稳定的不含苄醇的水溶液制剂
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
EP0396777A4 (en) * 1988-11-14 1991-03-13 Otsuka Pharmaceutical Co., Ltd. Interferon preparation for nasal administration
JPH0651642B2 (ja) * 1988-11-14 1994-07-06 大塚製薬株式会社 インターフェロン経鼻投与用製剤
CA2033714A1 (en) * 1990-01-25 1991-07-26 Alberto Ferro Pharmaceutical preparations
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon

Also Published As

Publication number Publication date
PL313655A1 (en) 1996-10-14
HK1012232A1 (en) 1999-07-30
CN1141808A (zh) 1997-02-05
CO4750807A1 (es) 1999-03-31
DE69603894T2 (de) 2000-04-20
BR9601276A (pt) 1998-01-13
JP2758154B2 (ja) 1998-05-28
ZA962553B (en) 1996-10-07
HU227643B1 (en) 2011-10-28
HUP9600857A3 (en) 1998-01-28
CZ287626B6 (en) 2001-01-17
SG52806A1 (en) 1998-09-28
MA23838A1 (fr) 1996-12-31
EP0736303A3 (en) 1997-02-26
AU5044696A (en) 1996-10-17
HU9600857D0 (en) 1996-05-28
AR002932A1 (es) 1998-05-27
ATE183650T1 (de) 1999-09-15
CZ99496A3 (en) 1996-10-16
DK0736303T3 (da) 2000-01-10
CY2194B1 (en) 2002-11-08
NO316801B1 (no) 2004-05-18
KR100212346B1 (ko) 1999-08-02
US5762923A (en) 1998-06-09
ES2136910T3 (es) 1999-12-01
DE69603894D1 (de) 1999-09-30
PE38897A1 (es) 1997-10-04
HUP9600857A2 (en) 1997-08-28
NO961322L (no) 1996-10-07
EP0736303B1 (en) 1999-08-25
CA2172664A1 (en) 1996-10-07
NO961322D0 (no) 1996-04-01
MY113594A (en) 2002-04-30
CN1066065C (zh) 2001-05-23
SA96160728B1 (ar) 2005-05-04
GR3031775T3 (en) 2000-02-29
IL117752A (en) 2000-11-21
CA2172664C (en) 2000-10-03
TW426523B (en) 2001-03-21
PL183873B1 (pl) 2002-07-31
TR199600287A2 (tr) 1997-03-21
EP0736303A2 (en) 1996-10-09
AU685356B2 (en) 1998-01-15
NZ286300A (en) 1997-05-26
RU2113845C1 (ru) 1998-06-27
IL117752A0 (en) 1996-08-04
JPH08283176A (ja) 1996-10-29

Similar Documents

Publication Publication Date Title
KR960037063A (ko) 인터페론 용액
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
FR2730637B1 (fr) Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
NZ332625A (en) Concentrated antibody preparation containing greater than 100 mg/ml of the antibody
KR920016587A (ko) 퍼옥시카복실산의 수성 현탁액
AU1446388A (en) Preparation of serine-n, n-diacetic acid and derivatives as complexing agents and detergents containing same
BR0012060A (pt) Composições de detergentes lìquidas aquosas compreendendo um sistema efervescente
PL319603A1 (en) Stable aqueous alpha interferon preparations
RU94028653A (ru) Фармацевтический препарат
MX9304972A (es) COMPOSICIONES DETERGENTES LIQUIDAS QUE CONTIENEN PROTEASA Y CIERTOS ACIDOS Y ESTERES ß-AMINOALQUILBORONICOS.
FR2696094B1 (fr) Nouvelles compositions pharmaceutiques contenant des cyclosporines.
BR9611096B1 (pt) composição farmacêutica compreendendo um extrato estável de hypericum perforatum l.
ATE193830T1 (de) Zubereitungen enthaltend leflunomide
MXPA02010648A (es) Formulaciones liquidas.
ES2137635T3 (es) Composicion liquida estable que contiene urato oxidasa y composicion liofilizada para su preparacion.
AR004168A1 (es) Composicion farmaceutica liquida vertible acuosa
WO1999035225A3 (de) Geschirrspülmittelformkörper mit tensiden
CO5570681A2 (es) Formulaciones de jarabe de ribavirina
BR9808722A (pt) Composições farmacêuticas de tizoxanida e nitazoxanida
KR950005325A (ko) 제약 조성물
TR200002293T2 (tr) Farmasötik bileşimler.
CO4920205A1 (es) Composicion para lavar la boca conteniendo clorhexidina y polivinilpirrolidona
AR009995A1 (es) Composicion detergente granulada que comprende la enzima isopeptidasa
ATE221730T1 (de) Enzym-konzentrat
KR960010001A (ko) 트레오닌을 함유한 알콜대사 촉진용 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130429

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20140430

Year of fee payment: 16

EXPY Expiration of term